STK25 and steatosis: Consistently, the inhibition of STK25 or MST3 activity in obese mice by genetic ablation or antisense oligonucleotide (ASO) treatment effectively ameliorates steatosis, inflammatory infiltration, nutritional fibrosis, and hepatocellular damage in the liver compared with control mice [14, 18–23].